Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2022 Aug 1;5(8):e2226551.
doi: 10.1001/jamanetworkopen.2022.26551.

Extent of Tumor Resection and Survival in Pediatric Patients With High-Grade Gliomas: A Systematic Review and Meta-analysis

Rami Hatoum  1 , Jia-Shu Chen  2 , Pascal Lavergne  3 , Nathan A Shlobin  4 , Andrew Wang  5   6 , Lior M Elkaim  7 , Philippe Dodin  8 , Charles P Couturier  9 , George M Ibrahim  10 , Aria Fallah  5   11 , Dominic Venne  12 , Sebastien Perreault  13 , Anthony C Wang  5   11 , Nada Jabado  14   15 , Roy W R Dudley  16 , Alexander G Weil  12   17   18
Affiliations
Meta-Analysis

Extent of Tumor Resection and Survival in Pediatric Patients With High-Grade Gliomas: A Systematic Review and Meta-analysis

Rami Hatoum et al. JAMA Netw Open. .

Abstract

Importance: Pediatric patients with high-grade gliomas have a poor prognosis. The association among the extent of resection, tumor location, and survival in these patients remains unclear.

Objective: To ascertain whether gross total resection (GTR) in hemispheric, midline, or infratentorial pediatric high-grade gliomas (pHGGs) is independently associated with survival differences compared with subtotal resection (STR) and biopsy at 1 year and 2 years after tumor resection.

Data sources: PubMed, EBMR, Embase, and MEDLINE were systematically reviewed from inception to June 3, 2022, using the keywords high-grade glioma, pediatric, and surgery. No period or language restrictions were applied.

Study selection: Randomized clinical trials and cohort studies of pHGGs that stratified patients by extent of resection and reported postoperative survival were included for study-level and individual patient data meta-analyses.

Data extraction and synthesis: Study characteristics and mortality rates were extracted from each article. Relative risk ratios (RRs) were pooled using random-effects models. Individual patient data were evaluated using multivariate mixed-effects Cox proportional hazards regression modeling. The PRISMA reporting guideline was followed, and the study was registered a priori.

Main outcomes and measures: Hazard ratios (HRs) and RRs were extracted to indicate associations among extent of resection, 1-year and 2-year postoperative mortality, and overall survival.

Results: A total of 37 studies with 1387 unique patients with pHGGs were included. In study-level meta-analysis, GTR had a lower mortality risk than STR at 1 year (RR, 0.69; 95% CI, 0.56-0.83; P < .001) and 2 years (RR, 0.74; 95% CI, 0.67-0.83; P < .001) after tumor resection. Subtotal resection was not associated with differential survival compared with biopsy at 1 year (RR, 0.82; 95% CI, 0.66-1.01; P = .07) but had decreased mortality risk at 2 years (RR, 0.89; 95% CI, 0.82-0.97; P = .01). The individual patient data meta-analysis of 27 articles included 427 patients (mean [SD] age at diagnosis, 9.3 [5.9] years), most of whom were boys (169 of 317 [53.3%]), had grade IV tumors (246 of 427 [57.7%]), and/or had tumors that were localized to either the cerebral hemispheres (133 of 349 [38.1%]) or midline structures (132 of 349 [37.8%]). In the multivariate Cox proportional hazards regression model, STR (HR, 1.91; 95% CI, 1.34-2.74; P < .001) and biopsy (HR, 2.10; 95% CI, 1.43-3.07; P < .001) had shortened overall survival compared with GTR but no survival differences between them (HR, 0.91; 95% CI, 0.67-1.24; P = .56). Gross total resection was associated with prolonged survival compared with STR for hemispheric (HR, 0.29; 95% CI, 0.15-0.54; P < .001) and infratentorial (HR, 0.44; 95% CI, 0.24-0.83; P = .01) tumors but not midline tumors (HR, 0.63; 95% CI, 0.34-1.19; P = .16).

Conclusions and relevance: Results of this study show that, among patients with pHGG, GTR is independently associated with better overall survival compared with STR and biopsy, especially among patients with hemispheric and infratentorial tumors, and support the pursuit of maximal safe resection in the treatment of pHGGs.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: None reported.

Figures

Figure 1.
Figure 1.. Forest Plot of Relative Risk (RR) for 1-Year Mortality for Gross Total Resection (GTR) vs Subtotal Resection (STR)
Blue squares indicate weight-adjusted relative risk ratios (RRs) of individual studies; horizontal black lines, 95% CIs; and blue diamond, the pooled relative RR estimate.
Figure 2.
Figure 2.. Forest Plot of Relative Risk (RR) for 2-Year Mortality for Gross Total Resection (GTR) vs Subtotal Resection (STR)
Blue squares indicate weight-adjusted relative risk ratios (RRs) of individual studies; horizontal black lines, 95% CIs; and blue diamond, the pooled relative RR estimate.
Figure 3.
Figure 3.. Kaplan-Meier Curve Comparing Overall Survival According to Extent of Resection
GTR indicates gross total resection; STR, subtotal resection.
See this image and copyright information in PMC

References

    1. Withrow DR, Berrington de Gonzalez A, Lam CJK, Warren KE, Shiels MS. Trends in pediatric central nervous system tumor incidence in the United States, 1998-2013. Cancer Epidemiol Biomarkers Prev. 2019;28(3):522-530. doi:10.1158/1055-9965.EPI-18-0784 - DOI - PMC - PubMed
    1. Finlay JL, Boyett JM, Yates AJ, et al. ; Childrens Cancer Group . Randomized phase III trial in childhood high-grade astrocytoma comparing vincristine, lomustine, and prednisone with the eight-drugs-in-1-day regimen. J Clin Oncol. 1995;13(1):112-123. doi:10.1200/JCO.1995.13.1.112 - DOI - PubMed
    1. Broniscer A, Gajjar A. Supratentorial high-grade astrocytoma and diffuse brainstem glioma: two challenges for the pediatric oncologist. Oncologist. 2004;9(2):197-206. doi:10.1634/theoncologist.9-2-197 - DOI - PubMed
    1. Lam S, Lin Y, Zinn P, Su J, Pan IW. Patient and treatment factors associated with survival among pediatric glioblastoma patients: a Surveillance, Epidemiology, and End Results study. J Clin Neurosci. 2018;47:285-293. doi:10.1016/j.jocn.2017.10.041 - DOI - PubMed
    1. Wang Y, Jiang T. Understanding high grade glioma: molecular mechanism, therapy and comprehensive management. Cancer Lett. 2013;331(2):139-146. doi:10.1016/j.canlet.2012.12.024 - DOI - PubMed